Drug profile · INN
troleandomycin
TAO
troleandomycin (TAO) is a 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — troleandomycin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
troleandomycin (TAO) is a 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN troleandomycin
Brand TAO
Mechanism 70S ribosome inhibitor
Target 70S ribosome
Route ORAL
Formulation CAPSULE
Mechanism of action
70S ribosome inhibitor
Primary target: 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is troleandomycin?
troleandomycin (TAO) is a 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for troleandomycin?
TAO is a marketed brand name for troleandomycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of troleandomycin?
troleandomycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.